Improvement in Immune Function due to Treatment with Indinavir despite Severe Immune Deficiency

Abstract

To study the virological, immunological and clinical effects of the protease inhibitor indinavir in human immunodeficiency virus (HlV)-infected patients with CD4 counts <50 cells/mm³, indinavir was added to prior treatment with nucleoside analogues in a prospective open-label study in 23 HIV-infected patients with median CD4 count of 10 cells/mm³ and median serum HIV-1 RNA load of 27508 copies/ml. Addition of indinavir induced a decrease in HIV-1 RNA levels to <400 copies/ml in 15 patients that was maintained until week 36 of the study in 8 (35%) patients. The median increase in CD4 cell counts was 92 cells/mm³ (range 55–258 cells/mm³) and in CD8 counts was 245 cells/mm³ (range 51–1552 cells/mm³) at week 30. The treatment induced a significant CD8 T cell expansion, consisting in the first 6 weeks of predominantly memory CD45RO⁺ cells and followed by expansion of naive cells from week 12 on, and a significant decrease in the proportion of activated CD8/CD38 cells. In addition, significant increases in T cell proliferation following stimulation with phytohaemagglutinin and significant decreases in the rates of spontaneous apoptosis of CD4⁺ and CD8⁺ T cells were observed. In conclusion, the addition of indinavir induced restoration of both memory and naive CD8 T cells. Corresponding evidence of improving T cell function, as assessed by enhanced lymphoproliferative capacity and diminished propensity to undergo apoptosis, provides evidence for treatment-induced regeneration of immune function even in patients with severe immunodeficiency.